Stem cell-derived exosomes have become a key area of interest for cell-free therapeutic tools due to their strong diagnostic and therapeutic potential in various diseases. They offer several advantages compared to cell-based approaches – for example, they have exceptional stability and biocompatibility, and can be delivered to target tissue easier than whole cells.
However, the use of exosomes as a cell-free therapeutic tool requires the production of clinically relevant amounts of high-quality vesicles. This requires an efficient manufacturing process that must be standardized, reproducible and scalable. Stirred-tank bioreactors can help to achieve this challenge, as they provide a controlled environment that can facilitate the standardized expansion of high-yield viable cells and enhance the reproducible production of extracellular vesicles.
In this application note, explore the suitability of BioBLU® 0.3c Single-Use Bioreactors – controlled by a DASbox® Mini Bioreactor System – in the production of exosomes secreted by human adipose-derived stem cells. This fully controlled system allows an expansion of high yield of viable cells and optimizes the production of high-quality extracellular vesicles in standardized culture conditions.
This content was supplied by Eppendorf.